Eli Lilly and Company will begin rollout of its first connected platform, the Tempo Personalised Diabetes Management Platform, later this year in the US. The technology aims to help adults living with type 1 or type 2 diabetes and clinicians make informed, data-backed decisions to manage treatment with Lilly insulins.

The platform consists of three key components – the Tempo Smart Button; a compatible app, TempoSmart; and a prefilled insulin pen, Tempo Pen – which work together to deliver personalised guidance for adults with diabetes.

The Smart Button was cleared by the US Food and Drug Administration on September 16. The compatible app was developed in partnership with Welldoc and is a private label iteration of the company's BlueStar, a diabetes management app, customised to receive insulin dose-related data from the Tempo Smart Button.

Healthcare providers will have access to a clinician hub, Tempo Insights, where they can access data shared by their patients through the app and track patients' progress.